KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Emergent BioSolutions (EBS) Receivables Refunds (2016 - 2020)

Emergent BioSolutions has reported Receivables Refunds over the past 11 years, most recently at $10.2 million for Q1 2020.

  • For Q1 2020, Receivables Refunds changed N/A year-over-year to $10.2 million; the TTM value through Mar 2020 reached $10.2 million, changed N/A, while the annual FY2019 figure was $4.6 million, 46.51% down from the prior year.
  • Receivables Refunds for Q1 2020 was $10.2 million at Emergent BioSolutions, up from $4.6 million in the prior quarter.
  • Over five years, Receivables Refunds peaked at $11.8 million in Q3 2016 and troughed at $2.4 million in Q4 2017.
  • A 5-year average of $7.3 million and a median of $7.0 million in 2018 define the central range for Receivables Refunds.
  • Biggest five-year swings in Receivables Refunds: tumbled 77.85% in 2016 and later skyrocketed 258.33% in 2018.
  • Year by year, Receivables Refunds stood at $10.0 million in 2016, then tumbled by 75.99% to $2.4 million in 2017, then skyrocketed by 258.33% to $8.6 million in 2018, then crashed by 46.51% to $4.6 million in 2019, then skyrocketed by 121.74% to $10.2 million in 2020.
  • Business Quant data shows Receivables Refunds for EBS at $10.2 million in Q1 2020, $4.6 million in Q4 2019, and $8.6 million in Q4 2018.